ReCode Therapeutics is a genetic medicines company that specializes in mRNA and gene correction therapeutics.
ReCode Therapeutics is a genetic medicines company that specializes in mRNA and gene correction therapeutics. Its selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a genetic medicines technology that enables precise delivery to target organs and cells beyond the liver.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jun 29, 2022 | Series B | $120M | 5 | Leaps by Bayer Matrix Capital Management | — | Detail |
Oct 21, 2021 | Series B | $210M | 12 | EcoR1 Capital Pfizer Venture Investments | — | Detail |
Mar 26, 2020 | Series A | $80M | 6 | Colt Ventures OrbiMed | — | Detail |
Feb 8, 2019 | Seed | $2M | — | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Leaps by Bayer | Yes | Series B |
Matrix Capital Management | Yes | Series B |
EcoR1 Capital | Yes | Series B |
Amgen Ventures | — | Series B |
Pfizer Venture Investments | — | Series B |
Sanofi Ventures | — | Series B |
Colt Ventures | — | Series B |
Hunt Technology Ventures | — | Series B |
MPM Capital | — | Series B |
NS Investment | — | Series B |